Kronos Bio to be Acquired by Concentra Biosciences for $0.57 Per Share Plus Contingent Value Right

Reuters05-01

Kronos Bio to be Acquired by Concentra Biosciences for $0.57 Per Share Plus Contingent Value Right

CAMBRIDGE, Mass., May 01, 2025 - Kronos Bio, Inc. (Nasdaq: KRON), a biotechnology company focused on developing small molecule therapeutics for cancer and other diseases, has announced a definitive merger agreement with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire Kronos Bio for $0.57 in cash per share, along with a contingent value right $(CVR)$. The CVR entitles shareholders to a percentage of the net proceeds from the potential disposition of certain product candidates and cost savings. The merger is anticipated to close by mid-2025, following a tender offer to acquire all outstanding shares of Kronos Bio Common Stock. Kronos Bio's Board of Directors has endorsed the acquisition as beneficial for shareholders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kronos Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9442754-en) on May 01, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2532072479?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-01 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532072479","market":"us","top_or_hot":-1,"title":"Kronos Bio to be Acquired by Concentra Biosciences for $0.57 Per Share Plus Contingent Value Right","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kronos Bio to be Acquired by Concentra Biosciences for $0.57 Per Share Plus Contingent Value Right\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CAMBRIDGE, Mass., May 01, 2025 - <a href=\"https://laohu8.com/S/KRON\">Kronos Bio, Inc.</a> (Nasdaq: KRON), a biotechnology company focused on developing small molecule therapeutics for cancer and other diseases, has announced a definitive merger agreement with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire Kronos Bio for $0.57 in cash per share, along with a contingent value right <a href=\"https://laohu8.com/S/CVR\">$(CVR)$</a>. The CVR entitles shareholders to a percentage of the net proceeds from the potential disposition of certain product candidates and cost savings. The merger is anticipated to close by mid-2025, following a tender offer to acquire all outstanding shares of Kronos Bio Common Stock. Kronos Bio's Board of Directors has endorsed the acquisition as beneficial for shareholders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kronos Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9442754-en) on May 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kronos Bio to be Acquired by Concentra Biosciences for $0.57 Per Share Plus Contingent Value Right</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKronos Bio to be Acquired by Concentra Biosciences for $0.57 Per Share Plus Contingent Value Right\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-01 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kronos Bio to be Acquired by Concentra Biosciences for $0.57 Per Share Plus Contingent Value Right\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CAMBRIDGE, Mass., May 01, 2025 - <a href=\"https://laohu8.com/S/KRON\">Kronos Bio, Inc.</a> (Nasdaq: KRON), a biotechnology company focused on developing small molecule therapeutics for cancer and other diseases, has announced a definitive merger agreement with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire Kronos Bio for $0.57 in cash per share, along with a contingent value right <a href=\"https://laohu8.com/S/CVR\">$(CVR)$</a>. The CVR entitles shareholders to a percentage of the net proceeds from the potential disposition of certain product candidates and cost savings. The merger is anticipated to close by mid-2025, following a tender offer to acquire all outstanding shares of Kronos Bio Common Stock. Kronos Bio's Board of Directors has endorsed the acquisition as beneficial for shareholders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kronos Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9442754-en) on May 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nNDL8JbRYx:1","article_id":"2532072479","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532072479","pubTimestamp":1746102638,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CAMBRIDGE, Mass., May 01, 2025 - Kronos Bio, Inc. , a biotechnology company focused on developing small molecule therapeutics for cancer and other diseases, has announced a definitive merger agreement with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire Kronos Bio for $0.57 in cash per share, along with a contingent value right . The CVR entitles shareholders to a percentage of the net proceeds from the potential disposition of certain product candidates and cost savings. The merger is anticipated to close by mid-2025, following a tender offer to acquire all outstanding shares of Kronos Bio Common Stock. Kronos Bio's Board of Directors has endorsed the acquisition as beneficial for shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","KRON":"Kronos Bio, Inc.","BK4112":"金融交易所和数据","BK4505":"高瓴资本持仓","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"Kronos Bio将被Concentra Biosciences以每股0.57美元外加或有价值权收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"KRON":0.9},"content_text":"Kronos Bio to be Acquired by Concentra Biosciences for $0.57 Per Share Plus Contingent Value Right\n    \n\n        CAMBRIDGE, Mass., May 01, 2025 - Kronos Bio, Inc. (Nasdaq: KRON), a biotechnology company focused on developing small molecule therapeutics for cancer and other diseases, has announced a definitive merger agreement with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire Kronos Bio for $0.57 in cash per share, along with a contingent value right $(CVR)$. The CVR entitles shareholders to a percentage of the net proceeds from the potential disposition of certain product candidates and cost savings. The merger is anticipated to close by mid-2025, following a tender offer to acquire all outstanding shares of Kronos Bio Common Stock. Kronos Bio's Board of Directors has endorsed the acquisition as beneficial for shareholders.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kronos Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9442754-en) on May 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2532072479","isCrawlerRequest":true}